News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Spectrum Pharmaceuticals, Inc. (SPPI) Announces the USPTO Has Granted Five-Year Extension for FOLOTYN® Patent


10/8/2012 9:42:28 AM

HENDERSON, Nev.--(BUSINESS WIRE)--Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that the United States Patent and Trademark Office (USPTO) has extended by five years the U.S. Patent No. 6,028,071, which covers FOLOTYN® (pralatrexate injection). The extension was granted through the Hatch-Waxman Act and postpones the original July 16, 2017 expiration date to July 16, 2022.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES